Outpatient care for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and treatment of patients undergoing cladribine (2C19) during alemtuzumab-based induction: a retrospective study by the Chronic Malignancies Working Party of the EBMT

Subcommittee Chronic Lymphocytic Leukemia (CLL)

Chair: Olivier Tournilhac, Vice-chair: Michel van Gelder

Number of first allogeneic transplants for CLL registered at EBMT per year

- Related
- Mismatched related
- Unrelated
- Total allograft

Ongoing studies

Allogeneic transplantation for CLL – Olivier Tournilhac and Michel van Gelder

- AlloSCT after Multiple PI (AMPi)
- AlloSCT after stopping ibritinib for intolerance or relapse (ASTHIR)
- Venetoclax before and after alloSCT for CLL (VenAC)

Autologous and allogeneic HSCT for Richter’s Syndrome (2008-2018) – Romain Guizé

The prognosis of Richter’s syndrome (RS) is very poor as a result of and resistance to salvage treatment and overall survival following Richter transformation is usually less than 1 year. In this context, both autologous and allogeneic transplantation are strategies that have been proposed and even recommended in consolidation when remission can be achieved. We propose to analyze transplantation in Richter syndrome, with the hope of determining prognostic factors predictive of evolution. We believe that this study is important given the recent development of BCR and BCL2L1, and the emergence of Richter syndromes in this context.

Upcoming manuscript

T-cell prolymphocytic leukemia: autologous transplantation – Joanna Drozd-Sokolowska

T-cell prolymphocytic leukemia is a rare entity with poor prognosis. While alemtuzumab administered intravenously is considered a golden standard first line, yielding response in >90% patients, there is a strong need for both remission consolidation and effective treatment of relapse. There are some studies reporting on autologous HSCT for these indications. Although ASCT might not provide a cure to T-PLL patients, it might be a viable option for older, less fit patients. The aim of this study is to evaluate the outcomes of T-PLL patients receiving autoSCT.

Oral Session 19: Lymphoma and CLL – Wednesday April 26th, 2023, 12:30 – 13:45

Location: Room 241

12:48 – 12:57
OS19-03 Consolidation of response with Autologous Hematopoietic Cell Transplantation for T-cell Prolymphocytic Leukemia. Retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – Joanna Drozd-Sokolowska

Most recent publications


Subcommittee Plasma Cell Disorders (PCD)

Chair: Patrick Hayden, Vice-chair: Meral Bekssay, Vice-chair: Stefan Schönland

Number of first allogeneic transplants for MM registered by EBMT per year

- Related
- Mismatched related
- Unrelated
- Total allograft

Recent publication

105 Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Cell Yields and Practice Variation-By-Country in Myeloma Patients undergoing First Autologous Stem Cell Transplants in EBMT centres (2012-2021) - Patrick Hayden

PB01 Long Term Outcomes Following Autologous Stem Cell Transplantation For Light Chain Deposition Disease: A Retrospective Study On Behalf Of The CMWP Of The EBMT - Laurent Garderet

PB02 International Differences In Baseline Characteristics And Practice Patterns In Patients With Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation - Laurent Garderet

BP03 Worldwide Network For Blood And Marrow Transplantation global study on baseline characteristics/clinical outcomes in Multiple Myeloma Patients undergoing ASCT, a study of 61,725 patients - Laurent Garderet

Subcommittee CAR-T PCD

Chair: Nico Gagelmann, Vice-chair: Laurent Garderet

Number of CAR-T for MM registered at EBMT per year

Most recent publication


Ongoing

Transplant versus CAR-T cell therapy for relapsed multiple myeloma: a joint study from the CMWP & CTTWP-EBMT – Nico Gagelmann & Laurent Garderet

Educational Meeting on Immunology and Cellular Therapy in Plasma Cell Disorders 24 November 2023 - 26 November 2023, Hamburg, Germany

On behalf of the Scientific Committee, we are pleased to invite you to the 1st Joint Educational Meeting of the Chronic Malignancies Working Party (CMWP) and the Cellular Therapy and Immunobiology Working Party (CTTW) of the EBMT. This event will present the most recent advances and new perspectives in the field of immunology and cellular therapy for multiple myeloma and plasma disorders, including current practical challenges and new patient-centered perspectives.

Most recent publications


cmwpebmt@lumc.nl

www.ebmt.org